Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 7/20 | 0.52 |
| ▸ | NPY1R | P25929 | 5/20 | 0.52 |
| ▸ | NPY2R | P49146 | 4/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.52 |
| ▸ | BACE1 | P56817 | 7/20 | 0.51 |
| ▸ | TFPI | P10646 | 1/20 | 0.50 |
| ▸ | CTSD | P07339 | 1/20 | 0.49 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30436211 | 0.92 | BACE1 (0.61) | NPY4RNPY1RNPY2RNPY5RBACE1 | |
| SCHEMBL30798743 | 0.92 | NPY4R (0.60) | NPY4RNPY1RNPY2RNPY5RBACE1 | |
| SCHEMBL29397501 | 0.90 | BACE1 (0.53) | BACE1TFPICTSDBACE2 | |
| SCHEMBL31257037 | 0.90 | BACE1 (0.60) | BACE1TFPICTSDBACE2 | |
| SCHEMBL30973970 | 0.90 | BACE1 (0.54) | BACE1CTSDBACE2 | |
| Opiorphin SCHEMBL23132680 | 0.90 | NPY4R (0.54) | NPY4RNPY1RNPY2RNPY5R | |
| Opiorphin SCHEMBL23133188 | 0.90 | NPY4R (0.54) | NPY4RNPY1RNPY2RNPY5R | |
| Opiorphin SCHEMBL20257129 | 0.90 | NPY4R (0.54) | NPY4RNPY1RNPY2RNPY5R | |
| Opiorphin SCHEMBL18328804 | 0.90 | NPY4R (0.54) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29993768 | 0.90 | NPY4R (0.55) | NPY4RNPY1RNPY2RNPY5RTFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | NPY4R 4433/4885NPY1R 3079/4885NPY2R 3236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.